Haemophilia treatments are used to prevent or control bleeding episodes for people with haemophilia.
The funded treatments for haemophilia changed. This means most people with haemophilia who access treatment needed to change the treatment they were using.
Two new longer acting treatments were funded for the first time. The longer acting treatments mean people with haemophilia will likely administer fewer injections.
Most people with haemophilia needed to change the brand of treatment they use, or the type of treatment they use. There was a six month transition period, beginning 1 May 2019 and ending 1 November 2019, to change treatments.
Haemophilia Treatment Centres supported affected people through the change.
New long acting treatments available from 1 May 2019
- From 1 May 2019, patients with haemophilia requiring prophylaxis treatment had funded access to extended half-life Factor VIII and Factor IX treatments (Adynovate and Alprolix).
- Clinicians decided in discussion with affected people if these longer acting treatments were right for them and what they needed to do to manage the change.
Changes for people with haemophilia A using Factor VIII
- From 1 May 2019, two new products were available as treatment options for people with haemophilia A – Advate and Adynovate.
- Advate is the preferred brand of short acting Factor VIII and Adynovate is the only funded long acting Factor VIII.
- From 1 May to 31 October 2019 Haemophilia Treatment Centres supported people change to Advate or Adynovate. Most people with haemophilia A then using Xyntha needed to change to Advate or Adynovate.
- From 1 November 2019 Xyntha was no longer funded for the majority of people with haemophilia A.
- People's clinician decided with them if it was appropriate to change brands and/or treatment. If the clinician considered that people should stay on their current brand of Factor VIII they applied to PHARMAC to fund Xyntha.
- People using Kogenate FS did not need to change treatment.
Changes for people with haemophilia B using Factor IX
- From 1 May 2019, two new products were available as treatment options for haemophilia B – RIXIBUS and Alprolix.
- RIXIBUS is now the only funded short acting Factor IX and Alprolix is the only funded long acting Factor IX.
- From 1 May to 31 October 2019, people's Haemophilia Treatment Centre supported them to change to RIXIBUS or Alprolix. All people with haemophilia B using BeneFIX needed to change to RIXIBUS or Alprolix
- From 1 November 2019, BeneFIX was longer funded.
Did everyone need to change their brand of treatment or the type of treatment?
No. Some people were able to stay on their existing treatment. Their clinician could apply for them to stay on Xyntha if the clinician considered it would be inappropriate to change treatments. RIXIBUS will continue to be funded.
The way people received their haemophilia treatment remained the same even if the treatments changed.
Who to contact
If you have any questions about which treatment is right for you, you should talk with your doctor or nurse at your Haemophilia Treatment Centre.
If you have any questions about the funding of your haemophilia treatments or access to these treatments, you can contact PHARMAC at firstname.lastname@example.org or 0800 660 050.
Last updated: 26 February 2020